The Phase II trial of Gemtuzumab Ozogamicin (Mylotarg) combined with standard dose cytarabine for relapsed AML presents a strategic opportunity for the SWOG Cancer Research Network and its collaborators, including the National Cancer Institute (NCI). Given the high unmet medical need in relapsed AML, this combination therapy could enhance treatment options and potentially capture market share in a competitive landscape dominated by established therapies. The trial's completion in 2010 positions it for potential follow-up studies or combination therapies, which could further solidify its market presence. The focus on CD33-positive patients aligns with current trends in targeted therapies, enhancing its commercial viability.